文献速递消化系统肿瘤

结直肠腹膜转移:减瘤手术联合或不联合HIPEC的III期随机试验(PRODIGE 7)

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2021-01-18

PRODIGE 7是一项在法国17个中心开展的随机、开放标签、III期试验,纳入265例可完全肉眼切除的结直肠癌腹膜转移患者,比较减瘤手术联合奥沙利铂HIPEC与单纯减瘤手术。结论认为单纯减瘤手术应作为治愈性策略的基石。

要点

  • 单纯减瘤手术应作为结直肠腹膜转移治愈性策略的基石。

核心结论

  • 在可完全肉眼切除的结直肠腹膜转移患者中,减瘤手术联合奥沙利铂HIPEC相比单纯减瘤手术未改善总生存,且术后晚期并发症更常见。
  • 研究提示单纯减瘤手术应作为结直肠腹膜转移治愈性治疗策略的基石。

研究设计与样本

  • 随机、开放标签、III期试验,在法国17个癌症中心开展。
  • 纳入265例18-70岁、组织学证实结直肠癌腹膜转移、WHO体力状态0或1、腹膜癌指数≤25且适合接受6个月全身化疗的患者。
  • 完成完全肉眼切除或残留肿瘤<1 mm的患者按1:1随机分配至减瘤手术联合奥沙利铂HIPEC组(133例)或单纯减瘤手术组(132例)。
  • 随机化采用最小化法,按中心、减瘤完整性、既往全身化疗线数和方案规定全身化疗时机分层。
  • 主要终点为总生存,在意向性治疗人群中分析;安全性在所有接受手术的患者中评估。

主要发现

  • 30天治疗相关死亡两组各2例(2%)。

关键数值与推荐

  • HIPEC采用奥沙利铂,闭腹技术360 mg/m²或开腹技术460 mg/m²。
  • HIPEC前20分钟静脉给予全身化疗:氟尿嘧啶400 mg/m²和亚叶酸20 mg/m²。
  • 所有患者术前和/或术后接受研究者选择的全身化疗,可联合靶向治疗。
  • 入组条件包括腹膜癌指数≤25、WHO体力状态0或1、预期寿命至少12周。

临床怎么用

  • 对于可完全肉眼切除的结直肠腹膜转移患者,不应常规在减瘤手术基础上加用奥沙利铂HIPEC。
  • 单纯减瘤手术可作为此类患者治愈性治疗策略的核心。
  • 需关注联合HIPEC患者术后60天≥3级不良事件风险增加。

局限性

  • 原文未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery has been associated with encouraging survival results in some patients with colorectal peritoneal metastases who were eligible for complete macroscopic resection. We aimed to assess the specific benefit of adding HIPEC to cytoreductive surgery compared with receiving cytoreductive surgery alone. METHODS: We did a randomised, open-label, phase 3 trial at 17 cancer centres in France. Eligible patients were aged 18-70 years and had histologically proven colorectal cancer with peritoneal metastases, WHO performance status of 0 or 1, a Peritoneal Cancer Index of 25 or less, and were eligible to receive systemic chemotherapy for 6 months (ie, they had adequate organ function and life expectancy of at least 12 weeks). Patients in whom complete macroscopic resection or surgical resection with less than 1 mm residual tumour tissue was completed were randomly assigned (1:1) to cytoreductive surgery with or without oxaliplatin-based HIPEC. Randomisation was done centrally using minimisation, and stratified by centre, completeness of cytoreduction, number of previous systemic chemotherapy lines, and timing of protocol-mandated systemic chemotherapy. Oxaliplatin HIPEC was administered by the closed (360 mg/m2) or open (460 mg/m2) abdomen techniques, and systemic chemotherapy (400 mg/m2 fluorouracil and 20 mg/m2 folinic acid) was delivered intravenously 20 min before HIPEC. All individuals received systemic chemotherapy (of investigators' choosing) with or without targeted therapy before or after surgery, or both. The primary endpoint was overall survival, which was analysed in the intention-to-treat population. Safety was assessed in all patients who received surgery. This trial is registed with ClinicalTrials.gov, NCT00769405, and is now completed. FINDINGS: Between Feb 11, 2008, and Jan 6, 2014, 265 patients were included and randomly assigned, 133 to the cytoreductive surgery plus HIPEC group and 132 to the cytoreductive surgery alone group. After median follow-up of 63·8 months (IQR 53·0-77·1), median overall survival was 41·7 months (95% CI 36·2-53·8) in the cytoreductive surgery plus HIPEC group and 41·2 months (35·1-49·7) in the cytoreductive surgery group (hazard ratio 1·00 [95·37% CI 0·63-1·58]; stratified log-rank p=0·99). At 30 days, two (2%) treatment-related deaths had occurred in each group.. Grade 3 or worse adverse events at 30 days were similar in frequency between groups (56 [42%] of 133 patients in the cytoreductive surgery plus HIPEC group vs 42 [32%] of 132 patients in the cytoreductive surgery group; p=0·083); however, at 60 days, grade 3 or worse adverse events were more common in the cytoreductive surgery plus HIPEC group (34 [26%] of 131 vs 20 [15%] of 130; p=0·035). INTERPRETATION: Considering the absence of an overall survival benefit after adding HIPEC to cytoreductive surgery and more frequent postoperative late complications with this combination, our data suggest that cytoreductive surgery alone should be the cornerstone of therapeutic strategies with curative intent for colorectal peritoneal metastases. FUNDING: Institut National du Cancer, Programme Hospitalier de Recherche Clinique du Cancer, Ligue Contre le Cancer.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Quénet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021. PMID: 33476595. doi:10.1016/S1470-2045(20)30599-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。